Company Profile

Immulogic Pharmaceutical Corporation
Profile last edited on: 4/15/2019      CAGE:       UEI:

Business Identifier: Allergy reagents and substance abuse vaccines diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

610 Lincoln Street
Waltham, MA 02451
   (781) 466-6000
Location: Multiple
Congr. District: 05
County: Middlesex

Public Profile

As of August 1999, ImmuLogic Pharmaceutical Corporation ceased operation . The company had operated as a biopharmaceutical company with a primary emphasis on the diagnosis and treatment of allergies and on the immunological treatment of addiction. In March 1999, the Board of Directors of ImmuLogic approved a plan to liquidate and dissolve the company. The Plan was approved by a majority of the stockholders of ImmuLogic in August 1999. The Plan was the end result of the restructuring, which began in 1997 and included the sale of the company's programs to Xenova plc, various sales of assets and IP and the sub-lease of its Waltham, Massachusetts facility, and a reduction in workforce.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1997 2 NIH $807,374
Project Title: Antibody Intervention in Cocaine Addiction
1994 1 NIH $75,000
Project Title: Cell reactivity to urshiol haptenated peptides

Key People / Management

  J Richard Crowley -- President

  Julian Bond

  Charles J Hackett

  Victoria Schad

Company News

There are no news available.